Orlando Romulo Hernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Orlando Romulo Hernández has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Pérez-Gómez
Department of Epidemiology of Chronic Diseases. National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, 28029, Spain
1 shared publication - Chaitanya Erady
PHG Foundation, University of Cambridge, Cambridge CB2 8RN, UK
1 shared publication - Chantal Babb de Villiers
Division of Human Genetics, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
1 shared publication - Cristina Barahona-López
Cancer and Environmental Epidemiology Unit, National Centre for Epidemiology, Instituto de Salud Carlos III Madrid Spain
1 shared publication - Dafina Petrova
CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain; Escuela Andaluza de Salud Pública, Granada, Spain; Medical Oncology, Hospital Universitario Virgen de las Nieves, Granada, Spain
1 shared publication - Elena Plans-Beriso
Department of Epidemiology of Chronic Diseases. National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, 28029, Spain
1 shared publication
Latest Publications
- Open Access
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9346
Biomarkers for Personalised Primary or Secondary Prevention in Cardiovascular Diseases: A Rapid Scoping Review
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally. Early detection and personalised prevention strategies are crucial for reducing the burden of CVD. The use of biomarkers plays a pivotal role in identifying individuals at risk and facilitating timely interventions. This rapid scoping review aims to identify and evaluate current research on biomarkers used for primary and secondary personalised prevention of CVD, highlighting evidence gaps and the integration of digital technologies. A comprehensive search was conducted in Medline and Embase databases from January 2020 to February 2023. Joanna Briggs Institute (JBI) Manual for Evidence Synthesis and PRISMA-ScR guidelines were followed. A total of 775 studies were included, with ischemic heart disease (IHD) and stroke being the most investigated CVDs. Molecular, cellular, imaging, physiological, and anthropometric biomarkers were included. Molecular biomarkers, particularly genetic and biochemical, were the most researched. For secondary prevention, there was considerable research using imaging biomarkers. Genetic biomarker research was the most frequent category of biomarker identified, particularly using variant analysis and polygenic scores, followed by biochemical, imaging, and physiological biomarkers. There was also evidence of the integration of artificial intelligence to enhance the predictive capabilities of these biomarkers. Despite progress, research gaps were identified for less common CVDs, such as aortic aneurysm and nonrheumatic valvular heart disease, and limited research investigating other molecular biomarker types, such as epigenetics and transcriptomics.
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9346
Open AccessBiomarkers for Personalised Primary or Secondary Prevention in Cardiovascular Diseases: A Rapid Scoping Review
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality globally. Early detection and personalised prevention strategies are crucial for reducing the burden of CVD. The use of biomarkers plays a pivotal role in identifying individuals at risk and facilitating timely interventions. This rapid scoping review aims to identify and evaluate current research on biomarkers used for primary and secondary personalised prevention of CVD, highlighting evidence gaps and the integration of digital technologies. A comprehensive search was conducted in Medline and Embase databases from January 2020 to February 2023. Joanna Briggs Institute (JBI) Manual for Evidence Synthesis and PRISMA-ScR guidelines were followed. A total of 775 studies were included, with ischemic heart disease (IHD) and stroke being the most investigated CVDs. Molecular, cellular, imaging, physiological, and anthropometric biomarkers were included. Molecular biomarkers, particularly genetic and biochemical, were the most researched. For secondary prevention, there was considerable research using imaging biomarkers. Genetic biomarker research was the most frequent category of biomarker identified, particularly using variant analysis and polygenic scores, followed by biochemical, imaging, and physiological biomarkers. There was also evidence of the integration of artificial intelligence to enhance the predictive capabilities of these biomarkers. Despite progress, research gaps were identified for less common CVDs, such as aortic aneurysm and nonrheumatic valvular heart disease, and limited research investigating other molecular biomarker types, such as epigenetics and transcriptomics.